Roles of conserved ectodomain cysteines of the rat P2X4 purinoreceptor in agonist binding and channel gating.
Mammalian P2X receptors contain 10 conserved cysteine residues in their ectodomains, which form five disulfide bonds (SS1-5). Here, we analyzed the relevance of these disulfide pairs in rat P2X4 receptor function by replacing one or both cysteines with alanine or threonine, expressing receptors in HEK293 cells and studying their responsiveness to ATP in the absence and presence of ivermectin, an allostenic modulator of these channels. Response to ATP was not altered when both cysteines forming the SS3 bond (C132-C159) were replaced with threonines. Replacement of SS1 (C116-C165), SS2 (C126-C149) and SS4 (C217-C227), but not SS5 (C261-C270), cysteine pairs with threonines resulted in decreased sensitivity to ATP and faster deactivation times. The maximum current amplitude was reduced in SS2, SS4 and SS5 double mutants and could be partially rescued by ivermectin in SS2 and SS5 double mutants. This response pattern was also observed in numerous single residue mutants, but receptor function was not affected when the 217 cysteine was replaced with threonine or arginine or when the 261 cysteine was replaced with alanine. These results suggest that the SS1, SS2 and SS4 bonds contribute substantially to the structure of the ligand binding pocket, while the SS5 bond located towards the transmembrane domain contributes to receptor gating.
Rokic
M B
MB
Department of Cellular and Molecular Neuroendocrinology, Institute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
Tvrdoňová
V
V
Vávra
V
V
Jindřichová
M
M
Obšil
T
T
Stojilkovic
S S
SS
Zemková
H
H
D000818:Animals; D001665:Binding Sites; D017124:Conserved Sequence; D003545:Cysteine / Q000737:chemistry* / Q000235:genetics; D057809:HEK293 Cells; D006801:Humans; D015640:Ion Channel Gating / Q000502:physiology; D051381:Rats; D058848:Receptors, Purinergic P2X4 / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism
D058848:Receptors, Purinergic P2X4; D003545:Cysteine
J Biol Chem. 2000 Sep 22;275(38):29361-7
10827197
J Biol Chem. 2006 Oct 27;281(43):32649-59
16954225
Annu Rev Physiol. 2009;71:333-59
18851707
J Neurochem. 2006 Feb;96(3):843-52
16371009
Mol Pharmacol. 2006 Feb;69(2):576-87
16282518
Biochem Biophys Res Commun. 2009 Mar 27;381(1):102-6
19351603
J Neurochem. 2007 Aug;102(4):1139-50
17663752
EMBO J. 1997 Jun 16;16(12):3446-54
9218787
Neuron. 2007 Apr 19;54(2):263-74
17442247
Mol Pharmacol. 2005 Apr;67(4):1078-88
15632318
J Biol Chem. 2004 Dec 17;279(51):53109-15
15475563
J Neurosci. 2002 May 15;22(10):3873-80
12019306
Biochem Biophys Res Commun. 2006 Oct 20;349(2):619-25
16949036
Nature. 2009 Jul 30;460(7255):592-8
19641588
J Neurochem. 2008 May;105(4):1264-75
18194442
J Biol Chem. 2000 Nov 3;275(44):34190-6
10940304
Mol Pharmacol. 2002 Feb;61(2):303-11
11809854
J Gen Physiol. 2004 Mar;123(3):281-93
14769846
Neuropharmacology. 2009 Jan;56(1):208-15
18657557
Nature. 2006 Aug 3;442(7102):527-32
16885977
Physiol Rev. 2002 Oct;82(4):1013-67
12270951
EMBO J. 1998 Jun 1;17(11):3016-28
9606184
J Biol Chem. 2007 Dec 21;282(51):36879-86
17962187
J Neurosci. 1999 Sep 1;19(17):7289-99
10460235
J Biol Chem. 2004 Mar 5;279(10):9043-55
14699168